Scintigraphic imaging of the adrenal glands

European Journal of Radiology

Volumn 41, Issue 2, 2002, Pages 123-130

  Kurtaran, Amir ^a   Traub, Tatjana ^a   Shapiro, Brahm ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

123I I MIBG; 131I MIBG; 131I Norcholesterol; Adrenal imaging; Scintigraphy

Indexed keywords

DIAGNOSTIC RADIOGRAPHY; DOSIMETRY;

SCINTIGRAPHIC IMAGING;

BIOLOGICAL ORGANS;

(3 IODOBENZYL)GUANIDINE I 125; (3 IODOBENZYL)GUANIDINE I 131; 6BETA IODOMETHYL 19 NORCHOLEST 5(10) EN 3BETA OL I 131;

ADRENAL CORTEX DISEASE; ADRENAL SCINTISCANNING; ARTICLE; CONTROLLED STUDY; DEVICE; DIAGNOSTIC VALUE; DRUG DISTRIBUTION; HUMAN; HYPERALDOSTERONISM; HYPERANDROGENISM; HYPERCORTISOLISM; IMAGE ANALYSIS; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT PLANNING;

3-IODOBENZYLGUANIDINE; ADOSTEROL; ADRENAL GLAND DISEASES; ADRENAL GLANDS; HUMANS; RADIOPHARMACEUTICALS;

EID: 0036168407     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0720-048X(01)00442-9     Document Type: Article

References (35)

1. Incidentally discovered adrenal masses
2. The incidentally discovered adrenal mass
3. Inzedentalome der nebenniere-eine übersicht
4. Distinguishing benign from malignant euadrenal masses
5. Efficacy of iodine-131-6β-methyl-iodo-19-norcholesterol scintigraphy and computed tomography in patients with primary aldosteronismus
6. Adrenal incidentoloma
7. I-123-Metaiodobenzylguanidine and In-111-Octreotide uptake in benign and malignant pheochromocytomas
8. Metaiodobenzylguanidine (MIBG) scintigraphy and computed tomography (CT) in clinical practice. Primary and secondary evaluation for localization of phaechromocytomas
9. Adrenal tissue characterization using MR imaging
10. Scintigraphic evaluation of clinically silent adrenal masses
11. Scintigraphy of incidentally discovered bilateral adrenal masses
12. MR imaging of the liver, kidneys, and adrenal glands
13. The diagnostic role of radionuclide imaging in evaluation of patients with nonhypersecreting adrenal masses
14. Questionability of the benefits of routine laparotomy as the surgical approach for pheochromocytomas and abdominal paragangliomas
15. Scintigraphic studies in adrenal hypertension
16. The synthesis of carbon-14 and radioiodinated compounds in the dichlorodiphenyldichloroethane (DDD) series
17. The adrenal scan: A current status report on radiotracers, dosimetry and clinical utility
18. The normal dexamethason suppression adrenal scintiscan
19. Scintigraphic localization of adrenal lesions in primary aldosteronism
20. Nebenierenrinde
21. Endocrinological applications in nuclear medicine
22. Normal adrenal asymmetry: Explanation and interpretation
23. The role of pharmacological manipulation in adrenal cortical scintigraphy
24. Value of bowel preparation in adrenocortical scintigraphy with NP 59
25. Interference of spironolactone on adrenocortical scintigraphy and other pitfalls in the location of adrenal abnormalities in primary aldosteronismus
26. Extra-adrenal pheochromocytomas
27. Pheochromocytoma and paraganglioma. Comparison of MR imaging with CT and I-131 MIBG scintigraphy
28. Neuroendocrine tumors
29. Comparison of somatostatin analog and metaiodobenyzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumours
30. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobezylguanidine (MIBG)
31. Radiolabeled adrenergic neuron blocking agents: Adrenomedullary imaging with 131I-iodobenzylguanidine
32. Imaging the primate adrenal medulla with 123I and 131I metaiodobenzylguanidine. Concise communication
33. The normal and abnormal distribution of the adrenomedullary imaging agent m-(I131) iodobenzylguanidine (I-131-MIBG) in man: Evaluation by scintigraphy
34. Inverse relationship between cardiac accumulation of 131I-MIBG and circulating catecholamines in suspected pheochromocytoma
35. Labetolol reduces 131I-MIBG uptake by pheochromocytoma and normal tissue